Eli Lilly reported Q1 CY2026 revenue of $19.8 billion. This figure represents 55.5% year-over-year growth. The revenue total beat analyst estimates by 13.7%.
The company achieved an adjusted EPS of $8.55. This earnings figure beat expectations by 25.9%.
Management raised full-year revenue guidance to a midpoint of $83.5 billion. This updated outlook is 2% above previous estimates. The company also increased its full-year adjusted EPS guidance to a midpoint of $36.25.
Eli Lilly stock climbed 9.43% to $931.50 during open market trading. The shares previously closed at $851.21 on April 29, 2026.